Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0319)
Name
Doranidazole
Synonyms
Doranidazole; 161903-10-2; Doranidazole [INN]; PR-69; 149838-23-3; PR-350; 4BLU68P76A; DTXSID3048817; 911XR034RX; NCGC00183013-01; RP 343; RP-343; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (2R,3S)-; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (S-(R*,S*))-; (2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol; (2R,3S)-3-((2-nitro-1H-imidazol-1-yl)methoxy)butane-1,2,4-triol; (2RS,3SR)-3-{(2-Nitroimidazol-1-yl)methoxy}butane-1,2,4-triol; 1,2,4-Butanetriol, 3-[(2-nitro-1H-imidazol-1-yl)methoxy]-, (2R,3S)-; PR 350; UNII-4BLU68P76A; UNII-911XR034RX; (2RS,3SR)-3-((2-NITROIMIDAZOL-1-YL)METHOXY)BUTANE-1,2,4-TRIOL; 1-((2',3'-Dihydroxy-1'-hydroxymethyl)propoxy)methyl-2-nitroimidazole; 3-((2-Nitro-1H-imidazol-1-yl)methoxy)-1,2,4-butanetriol (R*,S*)-; DORANIDAZOLE [JAN]; SCHEMBL8279381; CHEMBL2107741; DTXCID0028743; Tox21_113294; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (R*,S*)-; AKOS040751633; CAS-149838-23-3; 1-(1',3',4'-Trihydroxy-2'-butoxy)methyl-2-nitroimidazole; (2RSs,3SR)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol; (2R,3S)-3-((2-NITRO-1H-IMIDAZOL-1-YL)METHOXY)-1,2,4-BUTANETRIOL; 1,2,4-BUTANETRIOL, 3-((2-NITRO-1H-IMIDAZOL-1-YL)METHOXY)-, (2R,3S)-REL-

    Click to Show/Hide
Structure
Formula
C8H13N3O6
IUPAC Name
(2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol
Canonical SMILES
C1=CN(C(=N1)[N+](=O)[O-])COC(CO)C(CO)O
InChI
InChI=1S/C8H13N3O6/c12-3-6(14)7(4-13)17-5-10-2-1-9-8(10)11(15)16/h1-2,6-7,12-14H,3-5H2/t6-,7+/m1/s1
InChIKey
FIITXXIVUIXYMI-RQJHMYQMSA-N
PubChem CID
164486
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Glioblastoma ICD-11: 2A00
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model mGICs (Mouse glioma initiating cells)
mGSCs (Mouse glioma stem cells)
In Vivo Model
Female C57BL/6J mice (age 6-8 weeks) were anesthetized and placed into a stereotactic apparatus (David Kopf Instruments, Tujunga, CA). One thousand viable GSC-H cells were injected into the right hemisphere at a position 2 mm lateral to the bregma and 3 mm below the brain surface. After 10 days, animals were exposed to 15 Gy (radiation dose rate, 1.45 Gy/min) with or without prior injection of doranidazole (200 mg/kg, i.p.). Radiation was confined to the brain by protection of the body with a lead shield.

    Click to Show/Hide
Response regulation Doranidazole and misonidazole, but not metronidazole, manifested radiation-independent cytotoxicity for hypoxic glioma stem cells (GSCs) that was mediated by ferroptosis induced partially through blockade of mitochondrial complexes I and II and resultant metabolic alterations in oxidative stress responses.
References
Ref 1 2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche. Commun Biol. 2020 Aug 17;3(1):450. doi: 10.1038/s42003-020-01165-z.